RISPERDAL

LOE Approaching

risperidone

NDAORALTABLETPriority Review
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21

Mechanism of Action

unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite,…

Pharmacologic Class:

Atypical Antipsychotic

Clinical Trials (5)

NCT04418466Phase 1/2Completed

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

Started Apr 2021
NCT03978832Phase 4Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Started Jun 2019
69 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03390712N/AUnknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
NCT03220867Phase 1Withdrawn

Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants

Started Dec 2017
0
Healthy